Company intelligence / Profile preview

AHB Global

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

AHB Global is a clinical-stage biotechnology company focused on the discovery and development of next-generation multi-specific antibody therapeutics. Utilizing its proprietary AHB-Body platform, the company engineers innovative biologics designed to treat cancer and immunological disorders by engaging multiple pathways simultaneously. AHB Global was founded by a team of industry experts with a track record in biologics R&D and operates globally with offices in China and the United States. The company's lead programs include bispecific antibodies targeting immune checkpoints and tumor-associated antigens to improve patient outcomes in hard-to-treat cancers.

Therapeutic areas: OncologyImmunology
Modalities: Bispecific monoclonal antibodyMonoclonal antibodyBiologicMulti-specific antibody
Industry: Biotech

Beyond the preview

Go deeper on AHB Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AHB Global.

Explore the full profile